InsiderTrades.com logo
Andrew Fisher net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Andrew Fisher Biography and Net Worth

General Counsel of Verona Pharma PLC American Depositary Share

Mr. Fisher is an accomplished lawyer with more than 25 years of experience in the life sciences industry. He has a wealth of legal and strategic expertise supporting global, pre-clinical and clinical development, manufacturing and commercialization including launching four pulmonary therapies. Prior to joining Verona Pharma, Mr. Fisher founded and led a consulting practice, Andrew Fisher LLC, where he focused on providing strategic advice to start-up companies since September 2019. Previously, from 2001 until 2018, he held various roles at United Therapeutics Corporation, including Executive Vice President, Chief Strategy Officer and Deputy General Counsel, where he oversaw a variety of intellectual property, litigation, compliance, risk management, and investor and media relations matters, among other things. Mr. Fisher received a B.A. from University of Michigan and J.D. from George Washington University.

What is Andrew Fisher's net worth?

The estimated net worth of Andrew Fisher is at least $44.68 million as of August 1st, 2025. Mr. Fisher owns 417,903 shares of Verona Pharma PLC American Depositary Share stock worth more than $44,678,010 as of December 5th. This net worth approximation does not reflect any other assets that Mr. Fisher may own. Learn More about Andrew Fisher's net worth.

How old is Andrew Fisher?

Mr. Fisher is currently 54 years old. There are 4 older executives and no younger executives at Verona Pharma PLC American Depositary Share. The oldest executive at Verona Pharma PLC American Depositary Share is Dr. Kathleen A. Rickard M.D., Chief Medical Officer, who is 66 years old. Learn More on Andrew Fisher's age.

How do I contact Andrew Fisher?

The corporate mailing address for Mr. Fisher and other Verona Pharma PLC American Depositary Share executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma PLC American Depositary Share can also be reached via phone at 011-44-0-2032834200 and via email at [email protected]. Learn More on Andrew Fisher's contact information.

Has Andrew Fisher been buying or selling shares of Verona Pharma PLC American Depositary Share?

Andrew Fisher has not been actively trading shares of Verona Pharma PLC American Depositary Share during the last ninety days. Most recently, Andrew Fisher sold 9,584 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $13.14, for a transaction totalling $125,933.76. Following the completion of the sale, the general counsel now directly owns 417,903 shares of the company's stock, valued at $5,491,245.42. Learn More on Andrew Fisher's trading history.

Who are Verona Pharma PLC American Depositary Share's active insiders?

Verona Pharma PLC American Depositary Share's insider roster includes Christina Ackermann (Director), Michael Austwick (Director), James Brady (Director), Kenneth Cunningham (Director), Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Andrew Fisher (General Counsel), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Mahendra Shah (Director), Vikas Sinha (Director), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma PLC American Depositary Share's active insiders.

Are insiders buying or selling shares of Verona Pharma PLC American Depositary Share?

In the last year, insiders at the sold shares 30 times. They sold a total of 2,932,176 shares worth more than $29,558,114.16. The most recent insider tranaction occured on August, 1st when Director Kenneth Cunningham sold 10,808 shares worth more than $142,017.12. Insiders at Verona Pharma PLC American Depositary Share own 4.8% of the company. Learn More about insider trades at Verona Pharma PLC American Depositary Share.

Information on this page was last updated on 8/1/2025.

Andrew Fisher Insider Trading History at Verona Pharma PLC American Depositary Share

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/1/2025Sell9,584$13.14$125,933.76417,903View SEC Filing Icon  
6/16/2025Sell80,000$11.53$922,400.00359,999View SEC Filing Icon  
4/29/2025Sell26,072$8.98$234,126.56359,993View SEC Filing Icon  
See Full Table

Andrew Fisher Buying and Selling Activity at Verona Pharma PLC American Depositary Share

This chart shows Andrew Fisher's buying and selling at Verona Pharma PLC American Depositary Share by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Verona Pharma PLC American Depositary Share Company Overview

Verona Pharma PLC American Depositary Share logo
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $106.91
Low: $106.91
High: $106.91

50 Day Range

MA: $106.65
Low: $105.91
High: $106.95

2 Week Range

Now: $106.91
Low: $31.09
High: $106.93

Volume

N/A

Average Volume

1,457,608 shs

Market Capitalization

$9.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05